Enamel Matrix Derivative Proteins in Combination with a Flapless Approach for Periodontal Regeneration of Intrabony Defects: A 2-Year Prospective Case Series

2016 ◽  
Vol 36 (6) ◽  
pp. 797-805 ◽  
Author(s):  
Mario Aimetti ◽  
Francesco Ferrarotti ◽  
Giulia Mariani ◽  
Adriano Fratini ◽  
Marta Giraudi ◽  
...  
Keyword(s):  
Periodontal Regeneration ◽  
Case Series ◽  
Enamel Matrix Derivative ◽  
Enamel Matrix ◽  
Intrabony Defects ◽  
Prospective Case Series ◽  
Matrix Derivative

scholarly journals The Applications of Enamel Matrix Derivative in Implant Dentistry: A Narrative Review

Materials ◽  
2021 ◽  
Vol 14 (11) ◽  
pp. 3045
Author(s):  
Alice Alberti ◽  
Luca Francetti ◽  
Silvio Taschieri ◽  
Stefano Corbella
Keyword(s):  
Clinical Trials ◽  
Bone Regeneration ◽  
Randomized Clinical Trials ◽  
Periodontal Regeneration ◽  
Case Series ◽  
Titanium Implants ◽  
Enamel Matrix Derivative ◽  
Enamel Matrix ◽  
Implant Placement ◽  
Matrix Derivative

Enamel matrix derivative (EMD) has been successfully used for periodontal regeneration in intrabony defects. Recently, its use for peri-implant bone regeneration has also been hypothesized. The aim of this paper is to review preclinical and clinical studies investigating the use of EMD in correspondence with titanium implants, alone or as an adjunct to other biomaterials. Clinical trials and case series with more than five cases were included. Seven in vitro studies evaluated the effect of EMD, placed on titanium surfaces: An increase in proliferation and viability of osteoblasts was observed in all but two studies. An increase in TGF-β1 and osteocalcin production, alkaline phosphatase activity, and angiogenesis was also reported. Nine animal studies investigated the use of EMD at implant placement or for bone regeneration of peri-implant bone defects, and some of them reported a significant increase in bone formation or bone-to-implant contact. In four of eleven clinical trials on humans, EMD was successfully used at implant placement. The other seven evaluated the use of EMD in protocols for the treatment of peri-implantitis. In conclusion, the results of EMD seem promising, but further randomized clinical trials are needed to evaluate its efficacy.

scholarly journals Enamel Matrix Derivative and Autogenous Bone Graft for Periodontal Regeneration of Intrabony Defects in Humans: A Systematic Review and Meta-Analysis

Materials ◽  
2019 ◽  
Vol 12 (16) ◽  
pp. 2634 ◽  
Author(s):  
Marco Annunziata ◽  
Angelantonio Piccirillo ◽  
Francesco Perillo ◽  
Gennaro Cecoro ◽  
Livia Nastri ◽  
...  
Keyword(s):  
Bone Graft ◽  
Meta Analysis ◽  
Periodontal Regeneration ◽  
Autogenous Bone Graft ◽  
Enamel Matrix Derivative ◽  
Autogenous Bone ◽  
Controlled Trials ◽  
Enamel Matrix ◽  
Intrabony Defects ◽  
Matrix Derivative

The combination of enamel matrix derivative (EMD) with an autogenous bone graft in periodontal regeneration has been proposed to improve clinical outcomes, especially in case of deep non-contained periodontal defects, with variable results. The aim of the present systematic review and meta-analysis was to assess the efficacy of EMD in combination with autogenous bone graft compared with the use of EMD alone for the regeneration of periodontal intrabony defects. A literature search in PubMed and in the Cochrane Central Register of Controlled Trials was carried out on February 2019 using an ad-hoc search string created by two independent and calibrated reviewers. All randomized controlled trials (RCTs) comparing a combination of EMD and autogenous bone graft with EMD alone for the treatment of periodontal intrabony defects were included. Studies involving other graft materials were excluded. The requested follow-up was at least 6 months. There was no restriction on age or number of patients. Standard difference in means between test and control groups as well as relative forest plots were calculated for clinical attachment level gain (CALgain), probing depth reduction (PDred), and gingival recession increase (RECinc). Three RCTs reporting on 79 patients and 98 intrabony defects were selected for the analysis. Statistical heterogeneity was detected as significantly high in the analysis of PDred and RECinc (I2 = 85.28%, p = 0.001; I2 = 73.95%, p = 0.022, respectively), but not in the analysis of CALgain (I2 = 59.30%, p = 0.086). Standard difference in means (SDM) for CALgain between test and control groups amounted to −0.34 mm (95% CI −0.77 to 0.09; p = 0.12). SDM for PDred amounted to −0.43 mm (95% CI −0.86 to 0.01; p = 0.06). SDM for RECinc amounted to 0.12 mm (95% CI −0.30 to 0.55. p = 0.57). Within their limits, the obtained results indicate that the combination of enamel matrix derivative and autogenous bone graft may result in non-significant additional clinical improvements in terms of CALgain, PDred, and RECinc compared with those obtained with EMD alone. Several factors, including the surgical protocol used (e.g. supracrestal soft tissue preservation techniques) could have masked the potential additional benefit of the combined approach. Further well-designed randomized controlled trials, with well-defined selection criteria and operative protocols, are needed to draw more definite conclusions.

scholarly journals Enamel matrix derivative for the treatment of partially contained intrabony defects: 12-month results

2018 ◽  
Vol 64 (1) ◽  
pp. 27-34 ◽  
Author(s):  
S Corbella ◽  
A Alberti ◽  
E Calciolari ◽  
S Taschieri ◽  
L Francetti
Keyword(s):  
Enamel Matrix Derivative ◽  
Enamel Matrix ◽  
Intrabony Defects ◽  
Matrix Derivative
Sign in / Sign up

Export Citation Format

Share Document